AstraZeneca and Amgen’s Tezspire shows positive results in Phase 3 eosinophilic esophagitis trial

AstraZeneca and Amgen continue to co‑develop and co‑commercialize Tezspire, an anti‑inflammatory therapy already approved for asthma and chronic rhinosinusitis. The partners are preparing another FDA submission to broaden the drug’s label.

In the Phase 3 CROSSING trial, about 370 patients with symptomatic eosinophilic esophagitis received either a high dose, a low dose of Tezspire, or placebo. The study’s co‑primary endpoints were histologic remission and improvement in dysphagia frequency and severity.

At 24 weeks, patients treated with Tezspire achieved statistically significant improvements on both primary measures, and the benefits persisted through a 52‑week follow‑up. All secondary efficacy outcomes, including histologic severity, were also met, prompting the companies to plan a regulatory filing for this new indication.